Steven Cohen Roivant Sciences Ltd. Transaction History

Point72 Asset Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.36 - $11.74 $1.92 Million - $2.17 Million	185,226 Added 40.1%	647,126 $6.84 Million
Q1 2024 May 15, 2024	BUY	$9.87 - $11.8 $278,334 - $332,760	28,200 Added 6.5%	461,900 $4.87 Million
Q4 2023 Feb 14, 2024	SELL	$8.38 - $11.58 $19 Million - $26.3 Million	-2,272,700 Reduced 83.98%	433,700 $4.87 Million
Q3 2023 Nov 14, 2023	BUY	$9.76 - $13.19 $26.4 Million - $35.7 Million	2,706,400 New	2,706,400 $31.6 Million
Q1 2023 May 15, 2023	SELL	$6.92 - $9.98 $3.99 Million - $5.76 Million	-576,800 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$3.36 - $7.99 $1.94 Million - $4.61 Million	576,800 New	576,800 $4.61 Million
Q2 2022 Aug 15, 2022	BUY	$2.81 - $4.84 $2.46 Million - $4.24 Million	876,996 New	876,996 $3.57 Million

311

508M

1.26M

2.52M

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.94B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.